LLY241213P735000
- 0.20
- -0.21-51.22%
Eli Lilly and Co Newsroom
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $997
Bank of America resumes coverage of Eli Lilly and Co with a target price of $997.
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $997
Eli Lilly Analyst Ratings
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $994
Erste Group Downgrades Eli Lilly and Co(LLY.US) to Hold Rating
Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,000
The Trader: Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barron's
Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,000
Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barrons.com
Evercore Maintains Eli Lilly and Co(LLY.US) With Hold Rating
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $1,010
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $975
Wolfe Research Initiates Coverage On Eli Lilly With Outperform Rating, Announces Price Target of $1000
Eli Lilly Analyst Ratings
Wolfe Research Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $1,000
Daiwa Adjusts Price Target on Eli Lilly & Co. to $900 From $940, Maintains Outperform Rating
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $975
Truist Financial Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,029
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $975